United Therapeutics Corporation (UTHR)
NASDAQ: UTHRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
UTHR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $23.38B
- P/E (TTM)
- 19.52
- Forward P/E
- 17.92
- EPS (TTM)
- $27.92
- Dividend yield
- None
- 52-week range
- 409.07 – 609.35
- Day range
- 542.00 – 558.30
- Volume / Avg
- 1.01M / 649.55K
- Beta
- —
- Shares outstanding
- 42.89M
- Next earnings
- Nov 4, 2026
52-week range
UTHR stock today
United Therapeutics (UTHR) closed at $545.00 on Oct 7, up 0.62% (+$3.38), versus the S&P 500's 0.22% decline. Shares are 10.6% below their 52-week high of $609.35, set on May 6, 2026 and 33.2% above the 52-week low of $409.07, in the middle of the past year's range. UTHR is up 11.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 19.3%.
At 19.5x trailing earnings, United Therapeutics trades below the peer-group median of 23.8x. Its forward P/E of 17.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. United Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About United Therapeutics
Company profileUnited Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
- Headquarters
- Silver Spring, MD
- Employees
- 1,400
- IPO year
- 1999
- Website
- unither.com
Financial highlights
Full financialsIn fiscal 2025, United Therapeutics generated $3.18 billion in revenue, up 10.6% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $1.33 billion (+11.7% year over year), for a net margin of 41.9% versus a median of 37.6% in the prior 5 years. Gross margin was 87.9% (down from 89.2%) and operating margin 46.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B |
| Growth | +10.61% | +23.63% | +20.20% | +14.88% | +13.63% |
| Net income | $1.33B | $1.20B | $984.80M | $727.30M | $475.80M |
| EPS (diluted) | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$649.64+19.20%
- Strong buy 3
- Buy 8
- Hold 3
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $6.38
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $7.27 vs —
United Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INSMInsmed Incorporated | 101.74 | -3.32% | $22.22B | vs UTHR |
| ROIVRoivant Sciences Ltd. | 34.75 | -2.20% | $25.10B | vs UTHR |
| VTRSViatris Inc. | 17.49 | -0.29% | $20.09B | vs UTHR |
| ZTSZoetis Inc. Class A | 71.55 | +0.31% | $29.57B | vs UTHR |
| ALNYAlnylam Pharmaceuticals Inc. | 224.41 | +0.21% | $30.03B | vs UTHR |
| ASNDAscendis Pharma A/S | 228.41 | +1.04% | $15.03B | vs UTHR |
| SMMTSummit Therapeutics Inc. | 17.95 | +3.70% | $14.32B | vs UTHR |
| RPRXRoyalty Pharma plc Class A | 56.76 | +0.57% | $32.80B | vs UTHR |
Indexes, lists and sector
United Therapeutics stock FAQ
What is United Therapeutics's stock price today?
UTHR last traded at $545.00 as of Oct 7, 4:00 PM EDT, up 0.62% on the day. Prices are delayed at least 15 minutes.
Does United Therapeutics pay a dividend?
No. United Therapeutics does not currently pay a regular cash dividend.
When is United Therapeutics's next earnings date?
United Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $6.38.
What is UTHR's P/E ratio?
UTHR trades at a trailing P/E ratio of 19.52 and a forward P/E of 17.92, compared with a median of 23.8 for its closest peers.
Who is United Therapeutics's CEO?
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. is the chief executive officer of United Therapeutics Corporation, which has about 1,400 employees.
Has UTHR ever split its stock?
Yes. The most recent UTHR stock split was a 2-for-1 split on Sep 23, 2009.
What is the UTHR 52-week high?
The 52-week high for UTHR is $609.35 and the 52-week low is $409.07. The stock is currently 10.6% below its high.